Live feed08:15:00·34dPRReleasevia QuantisnowPharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 MillionByQuantisnow·Wall Street's wire, on your screen.JUNS· Jupiter Neurosciences Inc.Health Care
